Yale School of Public Health, Yale University, 60 College Street, New Haven, CT 06520, USA.
J Psychosom Res. 2012 Jul;73(1):68-73. doi: 10.1016/j.jpsychores.2012.02.011. Epub 2012 Apr 21.
Sexual function among testicular cancer survivors is a concern because affected men are of reproductive age when diagnosed. We conducted a case-control study among United States military men to examine whether testicular cancer survivors experienced impaired sexual function.
A total of 246 testicular cancer cases and 236 ethnicity and age matched controls were enrolled in the study in 2008-2009. The Brief Male Sexual Function Inventory (BMSFI) was used to assess sexual function.
Compared to controls, cases scored significantly lower on sex drive (5.77 vs. 5.18), erection (9.40 vs. 8.63), ejaculation (10.83 vs. 9.90), and problem assessment (10.55 vs. 9.54). Cases were significantly more likely to have impaired erection (OR 1.72; 95% CI 1.11-2.64), ejaculation (OR 2.27; 95% CI 1.32-3.91), and problem assessment (OR 2.36; 95% CI 1.43-3.90). In histology and treatment analysis, nonseminoma, chemotherapy and radiation treated cases risk of erectile dysfunction, delayed ejaculation, and/or problem assessment were greater when compared to controls.
This study provides evidence that testicular cancer survivors are more likely to have impaired sexual functioning compared to demographically matched controls. The observed impaired sexual functioning appeared to vary by treatment regimen and histologic subtype.
由于受影响的男性在诊断时处于生育年龄,因此睾丸癌幸存者的性功能是一个令人关注的问题。我们在美国军人中进行了一项病例对照研究,以检查睾丸癌幸存者是否存在性功能障碍。
2008 年至 2009 年,共有 246 例睾丸癌病例和 236 名种族和年龄匹配的对照者纳入了这项研究。使用简短男性性功能问卷(BMSFI)评估性功能。
与对照组相比,病例组的性欲评分显著较低(5.77 对 5.18),勃起功能评分(9.40 对 8.63),射精功能评分(10.83 对 9.90)和问题评估评分(10.55 对 9.54)。病例组勃起功能障碍(OR 1.72;95%CI 1.11-2.64),射精功能障碍(OR 2.27;95%CI 1.32-3.91)和问题评估(OR 2.36;95%CI 1.43-3.90)的发生几率显著更高。在组织学和治疗分析中,与对照组相比,非精原细胞瘤,化疗和放疗治疗的病例发生勃起功能障碍,延迟射精和/或问题评估的风险更高。
这项研究提供了证据,表明与人口统计学匹配的对照组相比,睾丸癌幸存者更有可能出现性功能障碍。观察到的性功能障碍似乎因治疗方案和组织学亚型而异。